{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,9,11]],"date-time":"2026-09-11T01:11:07Z","timestamp":1789089067234,"version":"build-2803163510"},"reference-count":68,"publisher":"Springer Science and Business Media LLC","issue":"12","license":[{"start":{"date-parts":[[2023,12,1]],"date-time":"2023-12-01T00:00:00Z","timestamp":1701388800000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.springernature.com\/gp\/researchers\/text-and-data-mining"},{"start":{"date-parts":[[2023,12,1]],"date-time":"2023-12-01T00:00:00Z","timestamp":1701388800000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/www.springernature.com\/gp\/researchers\/text-and-data-mining"}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["Curr Atheroscler Rep"],"published-print":{"date-parts":[[2023,12]]},"DOI":"10.1007\/s11883-023-01176-1","type":"journal-article","created":{"date-parts":[[2023,12,5]],"date-time":"2023-12-05T08:02:06Z","timestamp":1701763326000},"page":"1093-1099","update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":16,"title":["HDL as a Treatment Target: Should We Abandon This Idea?"],"prefix":"10.1007","volume":"25","author":[{"given":"Floran","family":"Begue","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Marie Laurine","family":"Apalama","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Gilles","family":"Lambert","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Olivier","family":"Meilhac","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","published-online":{"date-parts":[[2023,12,5]]},"reference":[{"key":"1176_CR1","doi-asserted-by":"publisher","first-page":"1277","DOI":"10.1016\/S0022-2275(20)34443-6","volume":"25","author":"RW Mahley","year":"1984","unstructured":"Mahley RW, Innerarity TL, Rall SC, Weisgraber KH. Plasma lipoproteins: apolipoprotein structure and function. J Lipid Res. 1984;25:1277\u201394.","journal-title":"J Lipid Res."},{"key":"1176_CR2","doi-asserted-by":"publisher","first-page":"S195","DOI":"10.1194\/jlr.R800034-JLR200","volume":"50","author":"K-A Rye","year":"2009","unstructured":"Rye K-A, Bursill CA, Lambert G, Tabet F, Barter PJ. The metabolism and anti-atherogenic properties of HDL. J Lipid Res. 2009;50:S195\u2013200.","journal-title":"J Lipid Res."},{"key":"1176_CR3","doi-asserted-by":"publisher","first-page":"27","DOI":"10.1007\/978-981-19-1592-5_3","volume":"1377","author":"Y Wu","year":"2022","unstructured":"Wu Y, Xu Y, Chen J, Zhao M, Rye K-A. HDL and endothelial function. Adv Exp Med Biol. 2022;1377:27\u201347.","journal-title":"Adv Exp Med Biol."},{"key":"1176_CR4","doi-asserted-by":"publisher","first-page":"737","DOI":"10.1161\/01.ATV.8.6.737","volume":"8","author":"PW Wilson","year":"1988","unstructured":"Wilson PW, Abbott RD, Castelli WP. High density lipoprotein cholesterol and mortality. The Framingham Heart Study. Arteriosclerosis. 1988;8:737\u201341.","journal-title":"Arteriosclerosis."},{"key":"1176_CR5","doi-asserted-by":"publisher","first-page":"2361","DOI":"10.1016\/j.jacc.2022.11.005","volume":"80","author":"M Vaduganathan","year":"2022","unstructured":"Vaduganathan M, Mensah GA, Turco JV, Fuster V, Roth GA. The global burden of cardiovascular diseases and risk. J Am Coll Cardiol. 2022;80:2361\u201371.","journal-title":"J Am Coll Cardiol."},{"key":"1176_CR6","doi-asserted-by":"publisher","first-page":"2478","DOI":"10.1093\/eurheartj\/ehx163","volume":"38","author":"CM Madsen","year":"2017","unstructured":"Madsen CM, Varbo A, Nordestgaard BG. Extreme high high-density lipoprotein cholesterol is paradoxically associated with high mortality in men and women: two prospective cohort studies. Eur Heart J. 2017;38:2478\u201386.","journal-title":"Eur Heart J."},{"key":"1176_CR7","doi-asserted-by":"publisher","first-page":"2349","DOI":"10.1056\/NEJMoa1605086","volume":"375","author":"AV Khera","year":"2016","unstructured":"Khera AV, Emdin CA, Drake I, Natarajan P, Bick AG, Cook NR, et al. Genetic risk, adherence to a healthy lifestyle, and coronary disease. N Engl J Med. 2016;375:2349\u201358.","journal-title":"N Engl J Med."},{"key":"1176_CR8","first-page":"e1046","volume":"139","author":"SM Grundy","year":"2019","unstructured":"Grundy SM, Stone NJ, Bailey AL, Beam C, Birtcher KK, Blumenthal RS, et al. 2018 AHA\/ACC\/AACVPR\/AAPA\/ABC\/ACPM\/ADA\/AGS\/APhA\/ASPC\/NLA\/PCNA Guideline on the management of blood cholesterol: executive summary: a report of the American College of Cardiology\/American Heart Association Task Force on Clinical Practice Guidelines. Circulation. 2019;139:e1046\u201381.","journal-title":"Circulation."},{"key":"1176_CR9","doi-asserted-by":"publisher","first-page":"H76","DOI":"10.1152\/ajpheart.00708.2019","volume":"319","author":"A Muscella","year":"2020","unstructured":"Muscella A, Stef\u00e0no E, Marsigliante S. The effects of exercise training on lipid metabolism and coronary heart disease. Am J Physiol Heart Circ Physiol. 2020;319:H76\u201388.","journal-title":"Am J Physiol Heart Circ Physiol."},{"key":"1176_CR10","doi-asserted-by":"publisher","first-page":"90","DOI":"10.1016\/j.clnesp.2021.01.033","volume":"42","author":"HO Santos","year":"2021","unstructured":"Santos HO, Lavie CJ. Weight loss and its influence on high-density lipoprotein cholesterol (HDL-C) concentrations: a noble clinical hesitation. Clin Nutr ESPEN. 2021;42:90\u20132.","journal-title":"Clin Nutr ESPEN."},{"key":"1176_CR11","doi-asserted-by":"publisher","first-page":"572","DOI":"10.1016\/S0140-6736(12)60312-2","volume":"380","author":"BF Voight","year":"2012","unstructured":"Voight BF, Peloso GM, Orho-Melander M, Frikke-Schmidt R, Barbalic M, Jensen MK, et al. Plasma HDL cholesterol and risk of myocardial infarction: a Mendelian randomisation study. Lancet. 2012;380:572\u201380.","journal-title":"Lancet."},{"key":"1176_CR12","doi-asserted-by":"publisher","first-page":"9208","DOI":"10.1038\/s41598-020-66027-4","volume":"10","author":"Y-D Tan","year":"2020","unstructured":"Tan Y-D, Xiao P, Guda C. In-depth Mendelian randomization analysis of causal factors for coronary artery disease. Sci Rep. 2020;10:9208.","journal-title":"Sci Rep."},{"key":"1176_CR13","doi-asserted-by":"publisher","first-page":"639","DOI":"10.1016\/S0022-2275(20)39245-2","volume":"7","author":"JA Glomset","year":"1966","unstructured":"Glomset JA, Janssen ET, Kennedy R, Dobbins J. Role of plasma lecithin:cholesterol acyltransferase in the metabolism of high density lipoproteins. J Lipid Res. 1966;7:639\u201348.","journal-title":"J Lipid Res."},{"key":"1176_CR14","doi-asserted-by":"publisher","first-page":"618","DOI":"10.1016\/S0140-6736(14)61217-4","volume":"384","author":"DJ Rader","year":"2014","unstructured":"Rader DJ, Hovingh GK. HDL and cardiovascular disease. Lancet. 2014;384:618\u201325.","journal-title":"Lancet."},{"key":"1176_CR15","doi-asserted-by":"publisher","first-page":"23742","DOI":"10.1074\/jbc.M102348200","volume":"276","author":"N Wang","year":"2001","unstructured":"Wang N, Silver DL, Thiele C, Tall AR. ATP-binding Cassette Transporter A1 (ABCA1) functions as a cholesterol efflux regulatory protein. J Biol Chem. 2001;276:23742\u20137.","journal-title":"J Biol Chem."},{"key":"1176_CR16","doi-asserted-by":"publisher","first-page":"3701","DOI":"10.1172\/JCI35470","volume":"118","author":"N Terasaka","year":"2008","unstructured":"Terasaka N, Yu S, Yvan-Charvet L, Wang N, Mzhavia N, Langlois R, et al. ABCG1 and HDL protect against endothelial dysfunction in mice fed a high-cholesterol diet. J Clin Invest. 2008;118:3701\u201313.","journal-title":"J Clin Invest."},{"key":"1176_CR17","doi-asserted-by":"publisher","first-page":"245","DOI":"10.1016\/S1388-1981(00)00153-0","volume":"1529","author":"A Jonas","year":"2000","unstructured":"Jonas A. Lecithin cholesterol acyltransferase. Biochim Biophys Acta-Mol Cell Biol Lipids. 2000;1529:245\u201356.","journal-title":"Biochim Biophys Acta-Mol Cell Biol Lipids."},{"key":"1176_CR18","doi-asserted-by":"publisher","first-page":"2216","DOI":"10.1172\/JCI32057","volume":"117","author":"X Wang","year":"2007","unstructured":"Wang X, Collins HL, Ranalletta M, Fuki IV, Billheimer JT, Rothblat GH, et al. Macrophage ABCA1 and ABCG1, but not SR-BI, promote macrophage reverse cholesterol transport in vivo. J Clin Invest. 2007;117:2216\u201324.","journal-title":"J Clin Invest."},{"key":"1176_CR19","doi-asserted-by":"publisher","first-page":"26898","DOI":"10.1074\/jbc.M010708200","volume":"276","author":"N Settasatian","year":"2001","unstructured":"Settasatian N, Duong M, Curtiss LK, Ehnholm C, Jauhiainen M, Huuskonen J, et al. The mechanism of the remodeling of high density lipoproteins by phospholipid transfer protein. J Biol Chem. 2001;276:26898\u2013905.","journal-title":"J Biol Chem."},{"key":"1176_CR20","doi-asserted-by":"publisher","first-page":"518","DOI":"10.1126\/science.271.5248.518","volume":"271","author":"S Acton","year":"1996","unstructured":"Acton S, Rigotti A, Landschulz KT, Xu S, Hobbs HH, Krieger M. Identification of scavenger receptor SR-BI as a high density lipoprotein receptor. Science. 1996;271:518\u201320.","journal-title":"Science."},{"key":"1176_CR21","doi-asserted-by":"publisher","first-page":"89","DOI":"10.1016\/j.atherosclerosis.2014.11.017","volume":"238","author":"LO Martinez","year":"2015","unstructured":"Martinez LO, Najib S, Perret B, Cabou C, Lichtenstein L. Ecto-F1-ATPase\/P2Y pathways in metabolic and vascular functions of high density lipoproteins. Atherosclerosis. 2015;238:89\u2013100.","journal-title":"Atherosclerosis."},{"key":"1176_CR22","doi-asserted-by":"publisher","first-page":"1255","DOI":"10.1016\/S0022-2275(20)36957-1","volume":"34","author":"A Tall","year":"1993","unstructured":"Tall A. Plasma cholesteryl ester transfer protein. J Lipid Res. 1993;34:1255\u201374.","journal-title":"J Lipid Res."},{"key":"1176_CR23","doi-asserted-by":"publisher","first-page":"161","DOI":"10.1016\/S1097-2765(01)00164-2","volume":"7","author":"A Chawla","year":"2001","unstructured":"Chawla A, Boisvert WA, Lee CH, Laffitte BA, Barak Y, Joseph SB, et al. A PPAR gamma-LXR-ABCA1 pathway in macrophages is involved in cholesterol efflux and atherogenesis. Mol Cell. 2001;7:161\u201371.","journal-title":"Mol Cell"},{"key":"1176_CR24","doi-asserted-by":"publisher","first-page":"2161","DOI":"10.1194\/jlr.R400010-JLR200","volume":"45","author":"AC Li","year":"2004","unstructured":"Li AC, Glass CK. PPAR- and LXR-dependent pathways controlling lipid metabolism and the development of atherosclerosis. J Lipid Res. 2004;45:2161\u201373.","journal-title":"J Lipid Res."},{"key":"1176_CR25","doi-asserted-by":"publisher","first-page":"1033","DOI":"10.1016\/S0022-2275(20)37227-8","volume":"38","author":"AS Plump","year":"1997","unstructured":"Plump AS, Azrolan N, Odaka H, Wu L, Jiang X, Tall A, et al. ApoA-I knockout mice: characterization of HDL metabolism in homozygotes and identification of a post-RNA mechanism of apoA-I up-regulation in heterozygotes. J Lipid Res. 1997;38:1033\u201347.","journal-title":"J Lipid Res."},{"key":"1176_CR26","doi-asserted-by":"publisher","first-page":"15090","DOI":"10.1074\/jbc.M008466200","volume":"276","author":"G Lambert","year":"2001","unstructured":"Lambert G, Sakai N, Vaisman BL, Neufeld EB, Marteyn B, Chan CC, et al. Analysis of glomerulosclerosis and atherosclerosis in lecithin cholesterol acyltransferase-deficient mice. J Biol Chem. 2001;276:15090\u20138.","journal-title":"J Biol Chem."},{"key":"1176_CR27","doi-asserted-by":"publisher","first-page":"12610","DOI":"10.1073\/pnas.94.23.12610","volume":"94","author":"A Rigotti","year":"1997","unstructured":"Rigotti A, Trigatti BL, Penman M, Rayburn H, Herz J, Krieger M. A targeted mutation in the murine gene encoding the high density lipoprotein (HDL) receptor scavenger receptor class B type I reveals its key role in HDL metabolism. Proc Natl Acad Sci. 1997;94:12610\u20135.","journal-title":"Proc Natl Acad Sci."},{"key":"1176_CR28","doi-asserted-by":"publisher","first-page":"9322","DOI":"10.1073\/pnas.96.16.9322","volume":"96","author":"B Trigatti","year":"1999","unstructured":"Trigatti B, Rayburn H, Vi\u00f1als M, Braun A, Miettinen H, Penman M, et al. Influence of the high density lipoprotein receptor SR-BI on reproductive and cardiovascular pathophysiology. Proc Natl Acad Sci. 1999;96:9322\u20137.","journal-title":"Proc Natl Acad Sci."},{"key":"1176_CR29","doi-asserted-by":"publisher","first-page":"73","DOI":"10.1038\/364073a0","volume":"364","author":"KR Marotti","year":"1993","unstructured":"Marotti KR, Castle CK, Boyle TP, Lin AH, Murray RW, Melchior GW. Severe atherosclerosis in transgenic mice expressing simian cholesteryl ester transfer protein. Nature. 1993;364:73\u20135.","journal-title":"Nature."},{"key":"1176_CR30","doi-asserted-by":"publisher","first-page":"1267","DOI":"10.1161\/CIRCULATIONAHA.107.704254","volume":"116","author":"H Tanigawa","year":"2007","unstructured":"Tanigawa H, Billheimer JT, Tohyama J, Zhang Y, Rothblat G, Rader DJ. Expression of cholesteryl ester transfer protein in mice promotes macrophage reverse cholesterol transport. Circulation. 2007;116:1267\u201373.","journal-title":"Circulation."},{"key":"1176_CR31","doi-asserted-by":"publisher","first-page":"478","DOI":"10.1056\/NEJM198108273050902","volume":"305","author":"H Mabuchi","year":"1981","unstructured":"Mabuchi H, Haba T, Tatami R, Miyamoto S, Sakai Y, Wakasugi T, et al. Effects of an inhibitor of 3-hydroxy-3-methylglutaryl coenzyme a reductase on serum lipoproteins and ubiquinone-10 levels in patients with familial hypercholesterolemia. N Engl J Med. 1981;305:478\u201382.","journal-title":"N Engl J Med."},{"key":"1176_CR32","doi-asserted-by":"publisher","first-page":"1489","DOI":"10.1056\/NEJMoa1501031","volume":"372","author":"JG Robinson","year":"2015","unstructured":"Robinson JG, Farnier M, Krempf M, Bergeron J, Luc G, Averna M, et al. Efficacy and safety of alirocumab in reducing lipids and cardiovascular events. N Engl J Med. 2015;372:1489\u201399.","journal-title":"N Engl J Med."},{"key":"1176_CR33","doi-asserted-by":"publisher","first-page":"1500","DOI":"10.1056\/NEJMoa1500858","volume":"372","author":"MS Sabatine","year":"2015","unstructured":"Sabatine MS, Giugliano RP, Wiviott SD, Raal FJ, Blom DJ, Robinson J, et al. Efficacy and safety of evolocumab in reducing lipids and cardiovascular events. N Engl J Med. 2015;372:1500\u20139.","journal-title":"N Engl J Med."},{"key":"1176_CR34","doi-asserted-by":"publisher","first-page":"2387","DOI":"10.1056\/NEJMoa1410489","volume":"372","author":"CP Cannon","year":"2015","unstructured":"Cannon CP, Blazing MA, Giugliano RP, McCagg A, White JA, Theroux P, et al. Ezetimibe added to statin therapy after acute coronary syndromes. N Engl J Med. 2015;372:2387\u201397.","journal-title":"N Engl J Med."},{"key":"1176_CR35","doi-asserted-by":"publisher","first-page":"e38","DOI":"10.1161\/ATV.0000000000000073","volume":"39","author":"CB Newman","year":"2019","unstructured":"Newman CB, Preiss D, Tobert JA, Jacobson TA, Page RL, Goldstein LB, et al. Statin safety and associated adverse events: a scientific statement from the American Heart Association. Arterioscler Thromb Vasc Biol. 2019;39:e38\u201381.","journal-title":"Arterioscler Thromb Vasc Biol."},{"key":"1176_CR36","doi-asserted-by":"publisher","first-page":"1353","DOI":"10.1056\/NEJMoa2215024","volume":"388","author":"SE Nissen","year":"2023","unstructured":"Nissen SE, Lincoff AM, Brennan D, Ray KK, Mason D, Kastelein JJP, et al. Bempedoic acid and cardiovascular outcomes in statin-intolerant patients. N Engl J Med. 2023;388:1353\u201364.","journal-title":"N Engl J Med."},{"key":"1176_CR37","doi-asserted-by":"publisher","first-page":"558","DOI":"10.1016\/0003-9861(55)90070-9","volume":"54","author":"R Altschul","year":"1955","unstructured":"Altschul R, Hoffer A, Stephen JD. Influence of nicotinic acid on serum cholesterol in man. Arch Biochem Biophys. 1955;54:558\u20139.","journal-title":"Arch Biochem Biophys."},{"key":"1176_CR38","doi-asserted-by":"publisher","first-page":"2255","DOI":"10.1056\/NEJMoa1107579","volume":"365","author":"The AIM-HIGH Investigators","year":"2011","unstructured":"The AIM-HIGH Investigators. Niacin in patients with low HDL cholesterol levels receiving intensive statin therapy. N Engl J Med. 2011;365:2255\u201367.","journal-title":"N Engl J Med."},{"key":"1176_CR39","doi-asserted-by":"publisher","first-page":"203","DOI":"10.1056\/NEJMoa1300955","volume":"371","author":"MJ Landray","year":"2014","unstructured":"The HPS2-THRIVE Collaborative Group, Landray MJ, Haynes R, Hopewell JC, Parish S, Aung T, et al. Effects of Extended-Release Niacin with Laropiprant in High-Risk Patients. N Engl J Med. 2014;371:203\u201312.","journal-title":"N Engl J Med"},{"key":"1176_CR40","doi-asserted-by":"publisher","first-page":"1237","DOI":"10.1056\/NEJM198711123172001","volume":"317","author":"MH Frick","year":"1987","unstructured":"Frick MH, Elo O, Haapa K, Heinonen OP, Heinsalmi P, Helo P, et al. Helsinki heart study: primary-prevention trial with Gemfibrozil in middle-aged men with dyslipidemia. N Engl J Med. 1987;317:1237\u201345.","journal-title":"N Engl J Med."},{"key":"1176_CR41","doi-asserted-by":"publisher","first-page":"410","DOI":"10.1056\/NEJM199908053410604","volume":"341","author":"HB Rubins","year":"1999","unstructured":"Rubins HB, Robins SJ, Collins D, Fye CL, Anderson JW, Elam MB, et al. Gemfibrozil for the secondary prevention of coronary heart disease in men with low levels of high-density lipoprotein cholesterol. N Engl J Med. 1999;341:410\u20138.","journal-title":"N Engl J Med."},{"key":"1176_CR42","doi-asserted-by":"publisher","first-page":"21","DOI":"10.1161\/01.CIR.102.1.21","volume":"102","author":"The BIP Study Group","year":"2000","unstructured":"The BIP Study Group. Secondary prevention by raising HDL cholesterol and reducing triglycerides in patients with coronary artery disease. Circulation. 2000;102:21\u20137.","journal-title":"Circulation."},{"key":"1176_CR43","doi-asserted-by":"publisher","first-page":"1154","DOI":"10.1001\/archinte.165.10.1154","volume":"165","author":"A Tenenbaum","year":"2005","unstructured":"Tenenbaum A, Motro M, Fisman EZ, Tanne D, Boyko V, Behar S. Bezafibrate for the secondary prevention of myocardial infarction in patients with metabolic syndrome. Arch Intern Med. 2005;165:1154\u201360.","journal-title":"Arch Intern Med."},{"key":"1176_CR44","doi-asserted-by":"publisher","first-page":"1849","DOI":"10.1016\/S0140-6736(05)67667-2","volume":"366","author":"The FIELD study","year":"2005","unstructured":"The FIELD study. Effects of long-term fenofibrate therapy on cardiovascular events in 9795 people with type 2 diabetes mellitus (the FIELD study): randomised controlled trial. Lancet. 2005;366:1849\u201361.","journal-title":"Lancet."},{"key":"1176_CR45","doi-asserted-by":"publisher","first-page":"1563","DOI":"10.1056\/NEJMoa1001282","volume":"362","author":"The ACCORD Study Group","year":"2010","unstructured":"The ACCORD Study Group. Effects of combination lipid therapy in type 2 diabetes mellitus. N Engl J Med. 2010;362:1563\u201374.","journal-title":"N Engl J Med."},{"key":"1176_CR46","doi-asserted-by":"publisher","first-page":"1923","DOI":"10.1056\/NEJMoa2210645","volume":"387","author":"A Das Pradhan","year":"2022","unstructured":"Das Pradhan A, Glynn RJ, Fruchart J-C, MacFadyen JG, Zaharris ES, Everett BM, et al. Triglyceride lowering with pemafibrate to reduce cardiovascular risk. N Engl J Med. 2022;387:1923\u201334.","journal-title":"N Engl J Med."},{"key":"1176_CR47","doi-asserted-by":"publisher","first-page":"1547","DOI":"10.1056\/NEJMoa2036205","volume":"385","author":"SM Francque","year":"2021","unstructured":"Francque SM, Bedossa P, Ratziu V, Anstee QM, Bugianesi E, Sanyal AJ, et al. A randomized, controlled trial of the Pan-PPAR agonist lanifibranor in NASH. N Engl J Med. 2021;385:1547\u201358.","journal-title":"N Engl J Med."},{"key":"1176_CR48","doi-asserted-by":"publisher","first-page":"1289","DOI":"10.1001\/jama.2016.13985","volume":"316","author":"MG Silverman","year":"2016","unstructured":"Silverman MG, Ference BA, Im K, Wiviott SD, Giugliano RP, Grundy SM, et al. Association between lowering LDL-C and cardiovascular risk reduction among different therapeutic interventions: a systematic review and meta-analysis. JAMA. 2016;316:1289\u201397.","journal-title":"JAMA."},{"key":"1176_CR49","doi-asserted-by":"publisher","first-page":"1","DOI":"10.1042\/bj2080001","volume":"208","author":"PJ Barter","year":"1982","unstructured":"Barter PJ, Hopkins GJ, Calvert GD. Transfers and exchanges of esterified cholesterol between plasma lipoproteins. Biochem J. 1982;208:1\u20137.","journal-title":"Biochem J."},{"key":"1176_CR50","doi-asserted-by":"publisher","first-page":"1234","DOI":"10.1056\/NEJM199011013231803","volume":"323","author":"A Inazu","year":"1990","unstructured":"Inazu A, Brown ML, Hesler CB, Agellon LB, Koizumi J, Takata K, et al. Increased high-density lipoprotein levels caused by a common cholesteryl-ester transfer protein gene mutation. N Engl J Med. 1990;323:1234\u20138.","journal-title":"N Engl J Med."},{"key":"1176_CR51","doi-asserted-by":"publisher","first-page":"2109","DOI":"10.1056\/NEJMoa0706628","volume":"357","author":"PJ Barter","year":"2007","unstructured":"Barter PJ, Caulfield M, Eriksson M, Grundy SM, Kastelein JJP, Komajda M, et al. Effects of Torcetrapib in patients at high risk for coronary events. N Engl J Med. 2007;357:2109\u201322.","journal-title":"N Engl J Med."},{"key":"1176_CR52","doi-asserted-by":"publisher","first-page":"2089","DOI":"10.1056\/NEJMoa1206797","volume":"367","author":"GG Schwartz","year":"2012","unstructured":"Schwartz GG, Olsson AG, Abt M, Ballantyne CM, Barter PJ, Brumm J, et al. Effects of dalcetrapib in patients with a recent acute coronary syndrome. N Engl J Med. 2012;367:2089\u201399.","journal-title":"N Engl J Med."},{"key":"1176_CR53","doi-asserted-by":"publisher","first-page":"2406","DOI":"10.1056\/NEJMoa1009744","volume":"363","author":"CP Cannon","year":"2010","unstructured":"Cannon CP, Shah S, Dansky HM, Davidson M, Brinton EA, Gotto AM, et al. Safety of anacetrapib in patients with or at high risk for coronary heart disease. N Engl J Med. 2010;363:2406\u201315.","journal-title":"N Engl J Med."},{"key":"1176_CR54","doi-asserted-by":"publisher","first-page":"1217","DOI":"10.1056\/NEJMoa1706444","volume":"377","author":"L Bowman","year":"2017","unstructured":"The HPS3\/TIMI55-REVEAL collaborative Group, Bowman L, Hopewell JC, Chen F, Wallendszus K, Stevens W, et al. Effects of Anacetrapib in Patients with Atherosclerotic Vascular Disease. N Engl J Med. 2017;377:1217\u201327.","journal-title":"N Engl J Med"},{"key":"1176_CR55","doi-asserted-by":"publisher","first-page":"1933","DOI":"10.1056\/NEJMoa1609581","volume":"376","author":"AM Lincoff","year":"2017","unstructured":"Lincoff AM, Nicholls SJ, Riesmeyer JS, Barter PJ, Brewer HB, Fox KAA, et al. Evacetrapib and cardiovascular outcomes in high-risk vascular disease. N Engl J Med. 2017;376:1933\u201342.","journal-title":"N Engl J Med."},{"key":"1176_CR56","doi-asserted-by":"publisher","first-page":"1672","DOI":"10.1038\/s41591-022-01936-7","volume":"28","author":"SJ Nicholls","year":"2022","unstructured":"Nicholls SJ, Ditmarsch M, Kastelein JJ, Rigby SP, Kling D, Curcio DL, et al. Lipid lowering effects of the CETP inhibitor obicetrapib in combination with high-intensity statins: a randomized phase 2 trial. Nat Med. 2022;28:1672\u20138. This phase 2 trial demonstrates the safety and efficacy of obicetrapib on top of statins in lowering atherogenic lipoproteins and apoB and increasing HDL and ApoA1, paving the way for a phase 3 trial to assess the potential clinical benefits of this novel CETP inhibitor.","journal-title":"Nat Med."},{"key":"1176_CR57","doi-asserted-by":"publisher","first-page":"894","DOI":"10.1194\/jlr.M800622-JLR200","volume":"50","author":"FM Sacks","year":"2009","unstructured":"Sacks FM, Rudel LL, Conner A, Akeefe H, Kostner G, Baki T, et al. Selective delipidation of plasma HDL enhances reverse cholesterol transport in vivo. J Lipid Res. 2009;50:894\u2013907.","journal-title":"J Lipid Res."},{"key":"1176_CR58","doi-asserted-by":"publisher","first-page":"2727","DOI":"10.1016\/j.jacc.2009.12.067","volume":"55","author":"R Waksman","year":"2010","unstructured":"Waksman R, Torguson R, Kent KM, Pichard AD, Suddath WO, Satler LF, et al. A first-in-man, randomized, placebo-controlled study to evaluate the safety and feasibility of autologous delipidated high-density lipoprotein plasma infusions in patients with acute coronary syndrome. J Am Coll Cardiol. 2010;55:2727\u201335.","journal-title":"J Am Coll Cardiol."},{"key":"1176_CR59","doi-asserted-by":"publisher","first-page":"597","DOI":"10.3390\/cells10030597","volume":"10","author":"A Wolska","year":"2021","unstructured":"Wolska A, Reimund M, Sviridov DO, Amar MJ, Remaley AT. Apolipoprotein mimetic peptides: potential new therapies for cardiovascular diseases. Cells. 2021;10:597. An excellent and comprehensive review on the potential of apolipoproteins mimetic peptides in cardiovascular health and beyond.","journal-title":"Cells."},{"key":"1176_CR60","doi-asserted-by":"publisher","first-page":"e6668506","DOI":"10.1155\/2021\/6668506","volume":"2021","author":"BA Di Bartolo","year":"2021","unstructured":"Di Bartolo BA, Cartland SP, Genner S, Manuneedhi Cholan P, Vellozzi M, Rye K-A, et al. HDL improves cholesterol and glucose homeostasis and reduces atherosclerosis in diabetes-associated atherosclerosis. J Diabetes Res. 2021;2021:e6668506.","journal-title":"J Diabetes Res."},{"key":"1176_CR61","doi-asserted-by":"publisher","first-page":"3277","DOI":"10.1093\/eurheartj\/ehu171","volume":"35","author":"J-C Tardif","year":"2014","unstructured":"Tardif J-C, Ballantyne CM, Barter P, Dasseux J-L, Fayad ZA, Guertin M-C, et al. Effects of the high-density lipoprotein mimetic agent CER-001 on coronary atherosclerosis in patients with acute coronary syndromes: a randomized trial. Eur Heart J. 2014;35:3277\u201386.","journal-title":"Eur Heart J."},{"key":"1176_CR62","doi-asserted-by":"publisher","first-page":"2292","DOI":"10.1001\/jama.290.17.2292","volume":"290","author":"SE Nissen","year":"2003","unstructured":"Nissen SE, Tsunoda T, Tuzcu EM, Schoenhagen P, Cooper CJ, Yasin M, et al. Effect of recombinant ApoA-I Milano on coronary atherosclerosis in patients with acute coronary syndromes: a randomized controlled trial. JAMA. 2003;290:2292\u2013300.","journal-title":"JAMA."},{"key":"1176_CR63","doi-asserted-by":"publisher","first-page":"815","DOI":"10.1001\/jamacardio.2018.2121","volume":"3","author":"SJ Nicholls","year":"2018","unstructured":"Nicholls SJ, Andrews J, Kastelein JJP, Merkely B, Nissen SE, Ray KK, et al. Effect of Serial infusions of CER-001, a Pre-\u03b2 high-density lipoprotein mimetic, on coronary atherosclerosis in patients following acute coronary syndromes in the CER-001 atherosclerosis regression acute coronary syndrome trial: a randomized clinical trial. JAMA Cardiol. 2018;3:815. This clinical trial shows that infusions of reconstituted HDL do not promote regression of coronary atherosclerosis in statin-treated patients with ACS and high plaque burden.","journal-title":"JAMA Cardiol."},{"key":"1176_CR64","doi-asserted-by":"publisher","first-page":"1675","DOI":"10.1001\/jama.297.15.jpc70004","volume":"297","author":"J-C Tardif","year":"2007","unstructured":"Tardif J-C, Gr\u00e9goire J, L\u2019Allier PL, Ibrahim R, Lesp\u00e9rance J, Heinonen TM, et al. Effects of reconstituted high-density lipoprotein infusions on coronary atherosclerosis: a randomized controlled trial. JAMA. 2007;297:1675\u201382.","journal-title":"JAMA."},{"key":"1176_CR65","doi-asserted-by":"publisher","first-page":"774418","DOI":"10.3389\/fcvm.2021.774418","volume":"8","author":"JJ Lee","year":"2021","unstructured":"Lee JJ, Chi G, Fitzgerald C, Kazmi SHA, Kalayci A, Korjian S, et al. Cholesterol efflux capacity and its association with adverse cardiovascular events: a systematic review and meta-analysis. Front Cardiovasc Med. 2021;8:774418.","journal-title":"Front Cardiovasc Med."},{"key":"1176_CR66","doi-asserted-by":"publisher","first-page":"9417","DOI":"10.3390\/ijms23169417","volume":"23","author":"AJ Nelson","year":"2022","unstructured":"Nelson AJ, Sniderman AD, Ditmarsch M, Dicklin MR, Nicholls SJ, Davidson MH, et al. Cholesteryl ester transfer protein inhibition reduces major adverse cardiovascular events by lowering apolipoprotein B levels. Int J Mol Sci. 2022;23:9417. A solid demonstration that the potential cardiovascular benefits of CETP inhibitors are caused by the reduction in atherogenic lipoproteins rather than an elevation in HDL concentrations.","journal-title":"Int J Mol Sci."},{"key":"1176_CR67","doi-asserted-by":"publisher","first-page":"754","DOI":"10.3390\/biomedicines10040754","volume":"10","author":"S Tanaka","year":"2022","unstructured":"Tanaka S, Begue F, Veeren B, Tran-Dinh A, Robert T, Tashk P, et al. First recombinant high-density lipoprotein particles administration in a severe ICU COVID-19 patient, a multi-omics exploratory investigation. Biomedicines. 2022;10:754.","journal-title":"Biomedicines."},{"key":"1176_CR68","doi-asserted-by":"publisher","first-page":"134","DOI":"10.1186\/s13054-020-02860-3","volume":"24","author":"S Tanaka","year":"2020","unstructured":"Tanaka S, Couret D, Tran-Dinh A, Duranteau J, Montravers P, Schwendeman A, et al. High-density lipoproteins during sepsis: from bench to bedside. Crit Care. 2020;24:134.","journal-title":"Crit Care"}],"container-title":["Current Atherosclerosis Reports"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s11883-023-01176-1.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/article\/10.1007\/s11883-023-01176-1\/fulltext.html","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s11883-023-01176-1.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2024,1,5]],"date-time":"2024-01-05T07:43:00Z","timestamp":1704440580000},"score":1,"resource":{"primary":{"URL":"https:\/\/link.springer.com\/10.1007\/s11883-023-01176-1"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2023,12]]},"references-count":68,"journal-issue":{"issue":"12","published-print":{"date-parts":[[2023,12]]}},"alternative-id":["1176"],"URL":"https:\/\/doi.org\/10.1007\/s11883-023-01176-1","relation":{},"ISSN":["1523-3804","1534-6242"],"issn-type":[{"value":"1523-3804","type":"print"},{"value":"1534-6242","type":"electronic"}],"subject":[],"published":{"date-parts":[[2023,12]]},"assertion":[{"value":"19 November 2023","order":1,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"5 December 2023","order":2,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Declarations"}},{"value":"The authors declare no competing interests.","order":2,"name":"Ethics","group":{"name":"EthicsHeading","label":"Conflict of Interest"}},{"value":"This article does not contain any studies with human or animal subjects performed by any of the authors.","order":3,"name":"Ethics","group":{"name":"EthicsHeading","label":"Human and Animal Rights and Informed Consent"}}]}}